Textbook Outcome (TO) has emerged as a composite quality metric in oncologic surgery, but its role in ovarian cancer–related peritoneal carcinomatosis remains unclear. This systematic review aimed to evaluate the definitions, achievement rates, and clinical relevance of TO in patients undergoing cytoreductive surgery for ovarian cancer with peritoneal carcinomatosis. A systematic literature search was conducted in PubMed, Embase, Scopus, and Web of Science following PRISMA 2020 guidelines. Studies evaluating composite outcomes or TO in ovarian cancer patients with peritoneal carcinomatosis were included. Data on study characteristics, TO definitions, achievement rates, and associations with oncologic outcomes were extracted. Methodological quality was assessed using the Newcastle–Ottawa Scale (NOS). From 47 identified records, three observational studies met the inclusion criteria. Definitions of TO varied across studies but consistently included complete cytoreduction as a core component. TO achievement rates ranged from 20.5
BACKGROUND:Although mechanical thrombectomy (MT) is an effective treatment for large vessel occlusion (LVO) with a high successful recanalization rate, MT failure (MTF) occurs in 10-15% of cases and is associated with unfavorable outcomes. However, little is known about the clinical, technical, and radiological reasons for MTF. We investigated the technical factors associated with MTF. METHODS:We conducted a retrospective analysis of consecutive patients with anterior LVO prospectively included in the ongoing observational multicenter ROSSETTI registry. Patients were categorized according to the success (≥mTICI 2b) or failure (<mTICI 2b) of the MT procedure. Baseline clinical and demographic characteristics, endovascular MT techniques, and angiographic and clinical outcomes were compared. Multivariate analysis for prediction of MTF was performed. RESULTS:We analyzed 4135 patients, including 325 patients (7.9%) with MTF. Patients in the MTF group had a significantly lower Alberta Stroke Program Early CT Score (ASPECTS) at baseline (8 (7-10) vs 9 (8-10)), longer time since last time seen well (279 min vs 262 min), increased MT procedure time (76 min vs 31 min), higher rate of complications (23% vs 4%), higher symptomatic intracerebral hemorrhage (21% vs 7.9%), higher 24 hour National Institutes of Health Stroke Scale score (19 vs 6), worse functional outcome at 3 months (modified Rankin Scale score 0-2, 15.6% vs 53%), and higher mortality (45% vs 20%). Four or more passes were an independent predictor of MTF (OR 3.46, 95% CI 2.58 to 4.63; P<0.001). None of the endovascular techniques demonstrated a higher likelihood of MTF. CONCLUSION:In this study, MTF in anterior circulation LVO was associated with a high complication rate and worse outcomes.
Cell metabolic rewiring is associated with resistance to venetoclax-azacitidine (Ven-Aza) combination therapy and relapse in acute myeloid leukemia (AML) patients. Drug-resistant cells exhibit an enhanced reliance on oxidative phosphorylation (OXPHOS) for energy production. Therefore, impairing mitochondrial metabolism represents an exciting strategy to face this unmet clinical need. We recently demonstrated that the specific activation of the phosphatase PP2A-B56α enhances the pro-apoptotic efficacy of venetoclax in AML. Here, through leveraging unbiased multi-omics-based approaches and using both genetic and pharmacological tools, we define key roles for the tumor suppressor PP2A-B56α complex in OXPHOS regulation and treatment response in disease-relevant AML models. From a translational perspective, the specific stabilization of PP2A-B56α heterocomplex with the novel PP2A molecular glue activator, RPT04402, reduces OXPHOS levels in treatment-resistant AML cells and improves treatment response in both Ven-Aza-sensitive and -resistant AML cell lines, primary cells, and in vivo models. Together, our work supports further research on targeted combination therapy approaches based on PP2A-B56α stabilization to counteract OXPHOS-related treatment resistance and improve AML responses in a patient population with historically poor outcomes.
Introduction Arboviral diseases are viral infections primarily transmitted by mosquitoes, with a growing global impact. Dengue and chikungunya virus have shown sustained expansion over recent decades, affecting regions previously considered non-endemic. The Region of Murcia presents factors that favour introduction and potential local transmission, including suitable climatic conditions, established presence of Aedes albopictus, and a high flow of travellers to areas with high incidence. Evaluating their evolution and epidemiological characteristics is essential to guide surveillance and support control efforts. Methods We analysed epidemiological surveillance data and clinical records of laboratory-confirmed acute dengue or chikungunya infections diagnosed in the Region of Murcia between 2014 and 2024. Results A total of 49 acute dengue infections were reported, showing an upward trend with a peak in 2024 (17 cases). Travel was related to 40.8% of cases for tourism and 44.9% for visits to friends and relatives, and two autochthonous cases were identified (2018). The most frequent regions of acquisition were Central America and the Caribbean (35%), South America (27%), and Southeast Asia (22%). For chikungunya, seven imported acute infections were recorded, with no autochthonous transmission and sporadic cases throughout the period, mostly acquired in Central and South America. Conclusion The sustained increase in imported dengue cases and the detection of isolated autochthonous transmission indicate a growing risk for the Region of Murcia. These findings highlight the need to strengthen epidemiological surveillance, vector control strategies, and preventive measures for travellers and the resident population, as well as early detection and management to prevent potential autochthonous transmission.
